CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of disease

摘要

The present invention relates to CX3CR1-targeting imaging agents and their use in treatment and diagnosis of diseases. Single domain CX3CR1-targeting polypeptides linked to detection labels and their use in in vivo imaging of atherosclerotic plaques are described. The CX3CR1-targeting imaging agents are useful in the treatment and diagnosis of CX3CR1-mediated diseases including atherosclerosis.

主权项

1. An imaging agent comprising a CX3CR1-targeting polypeptide linked to a detection label, wherein the CX3CR1-targeting polypeptide includes CDR1, CDR2 and CDR3 sequences selected from:
SEQ ID No: 141, 162 and 186, respectively; or SEQ ID No: 141, 163 and 187, respectively; or SEQ ID No: 141, 164 and 186, respectively; or SEQ ID No: 141, 166 and 186, respectively; or SEQ ID No: 141, 167 and 186, respectively; or SEQ ID No: 141, 167 and 189, respectively; or SEQ ID No: 141, 168 and 186, respectively; or SEQ ID No: 141, 168 and 187, respectively; or SEQ ID No: 141, 169 and 190, respectively; or SEQ ID No: 141, 170 and 186, respectively; or SEQ ID No: 141, 171 and 186, respectively; or SEQ ID No: 141, 174 and 186, respectively; or SEQ ID No: 141, 175 and 187, respectively; or SEQ ID No: 142, 165 and 188, respectively; or SEQ ID No: 142, 173 and 188, respectively; or SEQ ID No: 143, 164 and 186, respectively; or SEQ ID No: 144, 172 and 187, respectively; or SEQ ID No: 145, 172 and 187, respectively; or SEQ ID No: 141, 214 and 186, respectively; or SEQ ID No: 141, 215 and 186, respectively; or SEQ ID No: 141, 216 and 186, respectively; or SEQ ID No: 141, 217 and 186, respectively; or SEQ ID No: 141, 218 and 186, respectively; or SEQ ID No: 141, 219 and 186, respectively; or SEQ ID No: 141, 220 and 186, respectively; or SEQ ID No: 213, 221 and 186, respectively; or SEQ ID No: 213, 214 and 186, respectively; or SEQ ID No: 146, 176 and 191, respectively; or SEQ ID No: 146, 177 and 191, respectively; or SEQ ID No: 147, 178 and 192, respectively; or SEQ ID No: 147, 179 and 192, respectively; or SEQ ID No: 147, 179 and 194, respectively; or SEQ ID No: 148, 179 and 193, respectively; or SEQ ID No: 149, 179 and 192, respectively; or SEQ ID No: 149, 180 and 192, respectively; or SEQ ID No: 149, 181 and 192, respectively; or SEQ ID No: 149, 183 and 192, respectively; or SEQ ID No: 149, 185 and 192, respectively; or SEQ ID No: 150, 179 and 194, respectively; or SEQ ID No: 150, 182 and 194, respectively; or SEQ ID No: 151, 179 and 193, respectively; or SEQ ID No: 151, 182 and 194, respectively; or SEQ ID No: 151, 184 and 196, respectively; or SEQ ID No: 152, 179 and 195, respectively; or SEQ ID No: 153, 179 and 194, respectively; or SEQ ID No: 154, 182 and 194, respectively; or SEQ ID No: 155, 179 and 195, respectively; or SEQ ID No: 156, 181 and 192, respectively; or SEQ ID No: 157, 179 and 194, respectively; or SEQ ID No: 158, 179 and 192, respectively; or SEQ ID No: 159, 178 and 192, respectively; or SEQ ID No: 160, 179 and 194, respectively; or SEQ ID No: 161, 179 and 194, respectively;and wherein the detection label is a radio-isotope.